[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Longhena et al., 2017 - Google Patents

The Contribution of α‐Synuclein Spreading to Parkinson's Disease Synaptopathy

Longhena et al., 2017

View PDF @Full View
Document ID
14612817365773053554
Author
Longhena F
Faustini G
Missale C
Pizzi M
Spano P
Bellucci A
Publication year
Publication venue
Neural plasticity

External Links

Snippet

Synaptopathies are diseases with synapse defects as shared pathogenic features, encompassing neurodegenerative disorders such as Parkinson's disease (PD). In sporadic PD, the most common age‐related neurodegenerative movement disorder, nigrostriatal …
Continue reading at onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Similar Documents

Publication Publication Date Title
Longhena et al. The Contribution of α‐Synuclein Spreading to Parkinson’s Disease Synaptopathy
Ghiglieri et al. Alpha-synuclein: from early synaptic dysfunction to neurodegeneration
Fields et al. Targeting alpha-synuclein as a therapy for Parkinson’s disease
Vasili et al. Spreading of α-synuclein and tau: A systematic comparison of the mechanisms involved
Brás et al. Synucleinopathies: Where we are and where we need to go
Vargas et al. The prion-like spreading of α-synuclein: From in vitro to in vivo models of Parkinson’s disease
Choi et al. Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases
Tofaris Initiation and progression of α-synuclein pathology in Parkinson’s disease
Mor et al. The usual suspects, dopamine and alpha‐synuclein, conspire to cause neurodegeneration
Ottolini et al. Alpha-synuclein at the intracellular and the extracellular side: functional and dysfunctional implications
Villar‐Piqué et al. Structure, function and toxicity of alpha‐synuclein: the Bermuda triangle in synucleinopathies
George et al. α‐Synuclein: the long distance runner
Ghosh et al. α-synuclein aggregation and its modulation
Stroo et al. Cellular regulation of amyloid formation in aging and disease
Xu et al. Alpha‐Synuclein in Parkinson’s Disease: From Pathogenetic Dysfunction to Potential Clinical Application
Tillement et al. Alzheimer's disease: effects of β-amyloid on mitochondria
Kovacs et al. Intracellular processing of disease-associated α-synuclein in the human brain suggests prion-like cell-to-cell spread
Hunn et al. Impaired intracellular trafficking defines early Parkinson's disease
Brettschneider et al. Spreading of pathology in neurodegenerative diseases: a focus on human studies
Schorova et al. Sumoylation in synaptic function and dysfunction
Mokhtar et al. The Beta‐Amyloid Protein of Alzheimer’s Disease: Communication Breakdown by Modifying the Neuronal Cytoskeleton
Volpicelli-Daley et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death
Ono et al. Vitamin A and Alzheimer's disease
Hock et al. Prion‐like propagation as a pathogenic principle in frontotemporal dementia
Sarchione et al. Alpha-synuclein and lipids: the elephant in the room?